



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Beate Heissig

✉ heissig@juntendo.ac.jp

Koichi Hattori

✉ khattori@juntendo.ac.jp

RECEIVED 23 February 2024

ACCEPTED 01 March 2024

PUBLISHED 13 March 2024

CITATION

Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Tabe Y, Naito T, Takahashi K, Hattori K and Heissig B (2024) Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19.

Front. Immunol. 15:1390698.

doi: 10.3389/fimmu.2024.1390698

COPYRIGHT

© 2024 Yatsenko, Rios, Nogueira, Salama, Takahashi, Tabe, Naito, Takahashi, Hattori and Heissig. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19

Tetiana Yatsenko^{1,2}, Ricardo Rios³, Tatiane Nogueira³, Yousef Salama⁴, Satoshi Takahashi⁵, Yoko Tabe¹, Toshio Naito¹, Kazuhisa Takahashi^{1,6}, Koichi Hattori^{7,8*} and Beate Heissig^{1*}

¹Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Enzymes Chemistry and Biochemistry, Palladin Institute of Biochemistry of the National Academy of Science of Ukraine, Kyiv, Ukraine, ³Institute of Computing, Federal University of Bahia, Salvador, Bahia, Brazil, ⁴An-Najah Center for Cancer and Stem Cell Research, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine, ⁵Division of Clinical Precision Research Platform, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan, ⁶Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan, ⁷Center for Genome and Regenerative Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan, ⁸Department of Hematology/Oncology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan

KEYWORDS

COVID-19, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, interleukin-6, fibrinolysis, thrombosis, C-reactive protein, respiratory distress syndrome

A Corrigendum on

Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19

By Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Tabe Y, Naito T, Takahashi K, Hattori K and Heissig B (2024) *Front. Immunol.* 14:1299792. doi: 10.3389/fimmu.2023.1299792

In the published article, there was an error in the author list, and author Yousef Salama, along with their affiliation, was erroneously excluded. The corrected author list and affiliations appear below.

Tetiana Yatsenko^{1,2}, Ricardo Rios³, Tatiane Nogueira³, Yousef Salama⁴, Satoshi Takahashi⁵, Yoko Tabe¹, Toshio Naito¹, Kazuhisa Takahashi^{1,6}, Koichi Hattori^{7,8*} and Beate Heissig^{1*}

¹Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University School of Medicine, Tokyo, Japan

²Department of Enzymes Chemistry and Biochemistry, Palladin Institute of Biochemistry of the National Academy of Science of Ukraine, Kyiv, Ukraine

³Institute of Computing, Federal University of Bahia, Salvador, Bahia, Brazil

⁴An-Najah Center for Cancer and Stem Cell Research, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine;

⁵Division of Clinical Precision Research Platform, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan

6Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan

7Center for Genome and Regenerative Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan

8Department of Hematology/Oncology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

In the published article, there was an error in the **Author Contribution** section. Due to the fact author Yousef Salama was erroneously excluded, their contributions were not included in this section. The corrected **Author Contribution** section appears below.

Author contributions

BH: Conceptualization, Funding acquisition, Writing – original draft. RR: Formal analysis, Methodology, Software, Writing – review & editing. TNo: Formal analysis, Methodology, Software, Writing – review & editing. YS: Data curation, Writing – review & editing. ST: Funding acquisition, Writing – review & editing. YT:

Resources, Writing – review & editing. TNa: Resources, Writing – review & editing. KT: Resources, Writing – review & editing. KH: Conceptualization, Funding acquisition, Writing – review & editing. TY: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – review & editing, Writing – original draft.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.